Copyright
©The Author(s) 2020.
World J Pharmacol. Oct 28, 2020; 9(1): 1-12
Published online Oct 28, 2020. doi: 10.5497/wjp.v9.i1.1
Published online Oct 28, 2020. doi: 10.5497/wjp.v9.i1.1
Table 3 Medical treatment of nonalcoholic steatohepatitis
Insulin sensitization | |
PPAR receptor agonists | Tropifexor |
Glucagon like peptide 1 | NGM282 |
Farnesoid X receptor agonists | |
Inhibiting lipogenesis | |
Acetyl coenzyme a carboxylase inhibitors | |
Aramchol | |
Modulating lipid metabolism | |
Polyunsaturated fatty acids | |
Ezetimibe | |
Resmetirom | |
Inhibiting oxidative injury | |
Vitamin E | |
Anti-fibrotics | |
Simtuzumab | |
Galectin-3 inhibitors | |
Anti-inflammatory and anti-apoptotic agents | |
Caspase inhibitors | |
Chemokine receptor 2 and 5 inhibitors | |
Manipulating the intestinal microbiome | |
Antibiotics, probiotics, fecal microbiota transplantation | |
New and emerging treatments | |
Apical sodium dependent bile acid transporter inhibitors | |
Apoptosis signal kinase-1 inhibitors | |
Protein kinase inhibitors | |
Toll-like receptor 4 antagonists |
- Citation: Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12
- URL: https://www.wjgnet.com/2220-3192/full/v9/i1/1.htm
- DOI: https://dx.doi.org/10.5497/wjp.v9.i1.1